Filing Flows › Pacira BioSciences (PCRX) › Capital expenditures
Pacira BioSciences (PCRX) capital expenditures by quarter
Pacira BioSciences' capital expenditures were $3.6M in Q3 2026 (third quarter 2026), +171% from Q2 2026. Over the last 7 quarters it ranged from $218K (Q4 2025) to $8.5M (Q1 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $3.6M | +171% | -6% |
| Q2 2026 | $1.3M | -51% | -50% |
| Q1 2026 | $2.7M | 12× | -68% |
| Q4 2025 | $218K | -94% | — |
| Q3 2025 | $3.9M | +43% | — |
| Q2 2025 | $2.7M | -68% | — |
| Q1 2025 | $8.5M | — | — |
Q3 2026 at a glance
Pacira BioSciences, Q3 2026: revenue $177M (-2% year over year), operating margin 12.6%, net earnings $28.5M, operating cash flow $50.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is Pacira BioSciences' capital expenditures?
Pacira BioSciences' capital expenditures were $3.6M in Q3 2026 (third quarter 2026), +171% from Q2 2026.
How has Pacira BioSciences' capital expenditures changed?
Over the last 7 quarters it ranged from $218K (Q4 2025) to $8.5M (Q1 2025).